Biological E Appoints V Krishnakumar CEO Of Global Biopharma CDMO

Biological E's decision to install V Krishnakumar as CEO of its biopharma CDMO division signals a deliberate push to compete for Western outsourcing mandates at a moment when ADC and mRNA manufacturing capacity remains constrained globally. For QA directors and regulatory leads evaluating Asian CDMO partners, the appointment marks a structural shift in how the Hyderabad-based company intends to position its platform.

Krishnakumar will oversee a CDMO portfolio spanning vaccines, antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), recombinant proteins, and mRNA therapeutics. The breadth of that mandate reflects the complexity of the platform Biological E is building, each modality carries distinct process validation requirements, and aligning them under unified leadership has direct implications for technology transfer timelines and batch release consistency.

For plant heads and operations leads at sponsor companies, the practical read is around capacity commitments and GMP-readiness across modalities. ADC manufacturing in particular demands contained processing environments and rigorous sterility assurance protocols; mRNA programs carry their own cold-chain and in-process control requirements under 21 CFR Part 211 and equivalent ICH Q10 quality system expectations. A single executive accountable across all five modalities suggests Biological E is prioritising integrated oversight rather than siloed business units, a structure that can accelerate decision-making during tech transfer but also concentrates execution risk.

The appointment also lands against a broader trend: Western innovators seeking to diversify their CDMO supply chains beyond established European and North American providers, with Indian CDMOs increasingly shortlisted for biologics programs that previously defaulted to Asian peers in South Korea and China. Biological E's existing vaccine manufacturing credentials, including its Corbevax COVID-19 vaccine, give it a regulatory track record that new entrants cannot replicate quickly.

How Krishnakumar translates that legacy into a commercially competitive biologics CDMO offering, particularly on ADC and mRNA capacity, will be the measurable outcome sponsors and regulators watch through the next inspection cycle.

Source: Media4Growth via Indian Pharma Post, 2 October 2026.